August 31, 2013Open Access
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
Key Points
Key points are not available for this paper at this time.
Abstract
Serological tests using recombinant AQP4 antigen are significantly more sensitive than tissue-based IIF for detecting AQP4-IgG. Testing should precede immunotherapy; if negative, later-drawn specimens should be tested. AQP4-IgG-seronegative NMO is less frequent than previously reported and is clinically similar to AQP4-IgG-seropositive NMO.